TU2218, Anti-PD-1 antibody — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-30 in 8d
ESTIMATED |
READOUT
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in
Phase 1/2 · Advanced Solid Tumor |
TiumBio Co., Ltd. | TU2218, Anti-PD-1 antibody |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|